Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Albert Esquirol, Yolanda Guillén, Elena Bussaglia, Vanesa Criado, Maite Carricondo, Pamela Acha, Manel Esteller, Jorge Sierra, Francesc Solé, Anna Bigas, Josep F Nomdedeu

Blood (2022) 140 (Supplement 1): 11786–11787.

https://doi.org/10.1182/blood-2022-166117

Published: 2022

Journal Articles

Bone Marrow WT1 Levels In Long-Term Survivors Of Core-Binding Factor AML and Acute Promyelocytic Leukemia

Josep F Nomdedeu, MD, Montserrat Hoyos, Maite Carricondo, Elena Bussaglia, PhD, Maria-Concepcion Garcia-Dabrio, MD, Isabel Badell, MD, Camino Estivill, Ana Garrido, MD, Clara Martinez, MD, Salut Brunet, Anna Aventin, MD, Jorge Sierra, MD

Blood (2013) 122 (21): 4946.

https://doi.org/10.1182/blood.V122.21.4946.4946

Published: 2013

Journal Articles

WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.

Josep F Nomdedeu, MD, Montserrat Hoyos, Maite Carricondo, Elena Bussaglia, PhD, Camino Estivill, Jordi Esteve, MD, PhD, Mar Tormo, Rafael F Duarte, MD, PhD, Olga Salamero, MD, PAZ Queipo De Llano, MD, Joan Bargay, Inmaculada Heras, Josep M Marti-Tutusaus, Andreu Llorente, Josep-Maria Ribera, MD, PhD, David Gallardo, MD, PhD, Anna Aventin, MD, Salut Brunet, Jorge Sierra, MD

Blood (2012) 120 (21): 2524.

https://doi.org/10.1182/blood.V120.21.2524.2524

Published: 2012

Journal Articles

Feasibility of the AMLprofiler™ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach

Josep F Nomdedeu, MD, Eulalia Puigdecanet, Elena Bussaglia, PhD, Juan J Hernandez, Maite Carricondo, Camino Estivill, Josep M Marti-Tutusaus, Mar Tormo, Lurdes Zamora, PhD, Josep-Maria Ribera, MD, PhD, Lara Nonell, Anna Aventin, MD, Francesc Sole, Salut Brunet, Jorge Sierra, MD

Blood (2012) 120 (21): 4813.

https://doi.org/10.1182/blood.V120.21.4813.4813

Published: 2012

Journal Articles

WT1 Protein Expression in Myeloid Malignancies: An Immunohistochemical Study

Anna Mozos, MD, Elena Bussaglia, PhD, Maite Carricondo, Camino Estivill, Pablo Fuentes, PhD, Tatjana Dedjulia, Matilde Parreno, PhD, Anna Aventin, MD, Jorge Sierra, MD, Jaime Prat, MD, PhD, FRCPath, Josep Nomdedeu, MD

Blood (2011) 118 (21): 4886.

https://doi.org/10.1182/blood.V118.21.4886.4886

Published: 2011

Journal Articles

Correlation between WT1 Levels and Chimeric Transcripts in Core Binding Factor AML: Discrepancies Are Not Uncommon AML1-ETO Leukemias.

Adriana Lasa, PhD, Maite Carricondo, Daniela Cilloni, PhD, Salut Brunet, MD, Anna M. Aventin, MD, Jorge Sierra, MD, Josep F. Nomdedeu, MD

Blood (2006) 108 (11): 2309.

https://doi.org/10.1182/blood.V108.11.2309.2309

Published: 2006

NARROW

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Bone Marrow WT1 Levels In Long-Term Survivors Of Core-Binding Factor AML and Acute Promyelocytic Leukemia

WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.

Feasibility of the AMLprofiler™ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach

WT1 Protein Expression in Myeloid Malignancies: An Immunohistochemical Study

Correlation between WT1 Levels and Chimeric Transcripts in Core Binding Factor AML: Discrepancies Are Not Uncommon AML1-ETO Leukemias.

Email alerts

ASH Publications

American Society of Hematology

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Bone Marrow WT1 Levels In Long-Term Survivors Of Core-Binding Factor AML and Acute Promyelocytic Leukemia

WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.

Feasibility of the AMLprofiler™ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach

WT1 Protein Expression in Myeloid Malignancies: An Immunohistochemical Study

Correlation between WT1 Levels and Chimeric Transcripts in Core Binding Factor AML: Discrepancies Are Not Uncommon AML1-ETO Leukemias.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only